Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02180867 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
A Phase 2 study of Epithelioid Sarcoma and Alveolar Soft Part Sarcoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT02180867: Active Phase 2 study of Epithelioid Sarcoma and Alveolar Soft Part Sarcoma, sponsored by National Cancer Institute (NCI).
NCT02180867 is a Phase 2 study of Epithelioid Sarcoma and Alveolar Soft Part Sarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 140 participants, above the 84-participant average among 6 other Epithelioid Sarcoma trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02180867, a Phase 2 study of Epithelioid Sarcoma and Alveolar Soft Part Sarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether these therapies can be safely combined and if they work better when given together in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Primary Outcome
The dose of pazopanib that is feasible when given in combination with radiation or chemoradiation in pediatric unresected intermediate- and high-risk NRSTS patients. Initially, up to 10 patients (minimum of 3 patients ≥ 2 and \< 18 years of age and 3 patients ≥ 18 years of age) eligible for each of the two study cohorts were non-randomly assigned (to generate 8 patients evaluable for toxicity) to receive treatment with pazopanib at dose level 1. A protocol-defined list of pazopanib-associated ad
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Doxorubicin Hydrochloride
- DRUG Ifosfamide
- DRUG Pazopanib
- DRUG Pazopanib Hydrochloride
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- Kaiser Permanente-Anaheim - Anaheim
- AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Medical Center - Loma Linda
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
- The Kirklin Clinic at Acton Road - Birmingham
Arizona
- Banner Children's at Desert - Mesa
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-07-11 |
| Est. Completion | 2026-12-24 |
| Phase | Phase 2 |
What the registry record for NCT02180867 still lists
NCT02180867 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 84-participant average among 6 other Epithelioid Sarcoma trials with a reported enrollment target (67% higher).
The record links to 10 conditions, with Epithelioid Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT02180867 names 20 study sites across 5 states, led by Alaska, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02180867 about?
NCT02180867 is a clinical study titled "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery". This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation thera...
What is the current status of trial NCT02180867?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2014-07-11. Estimated completion is 2026-12-24.
What conditions does trial NCT02180867 study?
This clinical trial studies the following conditions: Epithelioid Sarcoma, Alveolar Soft Part Sarcoma, Fibrosarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma.
What interventions are being tested in trial NCT02180867?
The interventions under investigation include: Doxorubicin (DRUG), Doxorubicin Hydrochloride (DRUG), Ifosfamide (DRUG), Pazopanib (DRUG), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02180867?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02180867 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelioid Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Evaluate the Safety and Clinical Activity of HH2853
RECRUITING · Phase 1
-
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI